FIELD: medicine; pharmacology.
SUBSTANCE: method of treating or preventing at least one inflammatory condition in a patient, comprising administering tazarotene to a patient from 0.3 to 8 mg/day is disclosed, where the indicated amount of administered tazarotene inhibits the activation of NKT cells of type I patient, where the inflammatory condition is selected from the group consisting of fatty liver disease, alcohol-induced hepatitis, non-alcoholic steatosis hepatitis, cirrhosis, acute cirrhosis, idiopathic hepatitis, viral hepatitis (A, B, C and others), inflammatory hepatitis associated with hepatobiliary carcinoma, alcohol-induced liver damage, alcohol-related liver disease, hepatic steatosis and alcoholic cirrhosis and method of inhibiting the activation of type I NKT cells. Method of treatment further includes administration of sulfatide to activate type II NKT cells, which significantly inhibits the secretion of gamma interferon by type I NKT cells.
EFFECT: technical result consists in reducing inflammation mediated by type I NKT cells; in alcoholic liver disease, the proliferation of these cells decreased, but their number did not decrease.
32 cl, 18 dwg, 19 ex, 1 tbl
